Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PN-152, 243/PN-196, 444 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PN-152,243)/PN-196,444 | DRUG | - |
Inclusion Criteria: * Patients must be newly diagnosed with moderate or high-grade sarcoma and be receiving AI (Adriamycin/Ifosfamide) chemotherapy Exclusion Criteria: * Patients must not have active bleeding (exclusions do apply) or history of platelet disorder
Top 20 of 30 competitors
PN-152,243/PN-196,444 is an investigational small molecule being studied for the prevention of thrombocytopenia in patients with sarcoma. It is being developed by Pfizer, Inc. (NYSE: PFE). The drug is currently in Phase 3 clinical development.
PN-152,243/PN-196,444 is being developed by Pfizer, Inc. (NYSE: PFE). The company is conducting clinical trials to evaluate the drug's safety and efficacy in preventing thrombocytopenia in patients with sarcoma.
PN-152,243/PN-196,444 is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 3 trial has been completed to assess its safety and efficacy in preventing thrombocytopenia in sarcoma patients.
PN-152,243/PN-196,444 has one completed Phase 3 clinical trial, NCT00038311, titled "Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia." The trial enrolled 120 participants with sarcoma in the United States and was completed.
PN-152,243 and PN-196,444 are both names used for the same investigational drug, referred to as PN-152,243/PN-196,444. This drug is being studied for the prevention of thrombocytopenia in patients with sarcoma.